Watch for presentation of full interim data at an upcoming medical congress and for regulatory submission timelines. The study continues blinded to week 105 for eGFR data; any early regulatory filing would be a further catalyst.
Price Chart
Executive Summary
Ionis and partner Roche reported positive prespecified interim results from the Phase 3 IMAgINATION study of sefaxersen in IgA nephropathy. The study met its primary endpoint with statistically significant and clinically meaningful proteinuria reduction at 37 weeks, positioning sefaxersen as a potential best-in-class therapy. This is a major pipeline de-risking event for Ionis, as positive Phase 3 data on a partnered asset with a large addressable market significantly increases the probability of future milestone payments and royalties.
Key Facts
- Phase 3 IMAgINATION study met its primary endpoint with statistically significant and clinically meaningful proteinuria reduction at 37 weeks.
- Sefaxersen is a once-monthly subcutaneous injection targeting complement factor B, the first RNA-targeted therapy for IgAN.
- The study enrolled 459 patients randomized 1:1 to sefaxersen or placebo for 105 weeks.
- Safety profile consistent with prior data; no new safety signals identified.
- Roche licensed sefaxersen from Ionis; Ionis received upfront, license fee, and development milestones, and is eligible for regulatory/sales milestones and tiered royalties.
- IgAN affects at least 25 adults per million worldwide annually; up to 50% of patients progress to end-stage kidney disease within 20 years.
Financial Impact
Positive interim Phase 3 data significantly de-risks sefaxersen, unlocking potential regulatory and sales milestone payments and tiered royalties from Roche. No specific dollar amounts disclosed in the filing.
Risk Factors
- Interim data may not fully predict long-term kidney function outcomes at week 105.
- Regulatory approval is not guaranteed; health authority feedback could require additional data.
- Competition in IgAN from existing therapies (e.g., Tarpeyo, Filspari) and other pipeline candidates could limit commercial potential.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-037371 |
| Document: ef20082626_ex99-1.htm | 0001140361-26-037371 |
| Document: 0001140361-26-037371-index-headers.html | 0001140361-26-037371 |
| Document: 0001140361-26-037371-index.html | 0001140361-26-037371 |
| Document: 0001140361-26-037371.txt | 0001140361-26-037371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $43.23 | awaiting T+20 | — | $43.96 (+1.69%) |
Oct 23, 2026 4d ago | 8-K | $42.93 | awaiting T+20 | — | $43.96 (+2.40%) |
Oct 21, 2026 6d ago | 8-K | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Oct 21, 2026 6d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $43.96 (+0.07%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $43.96 (+22.48%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $43.96 (−24.32%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $43.96 (−19.32%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $43.96 (−18.65%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.96 (−24.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers